Optimal Timing of Radiotherapy with Alternating/Sequential Radio-Chemotherapy for Limited-stage Small Cell Lung Cancer

Wang, Li-Jie; Liu, Xiu-Ju; Guan, Yan; Zhang, Chu-Feng; Wang, Peng; Li, Yan; Guo, Qi-Sen

추천

검색

자료유형: 학술저널

저자정보: Wang, Li-Jie (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences) Liu, Xiu-Ju (Department of Medical Oncology, Shandong Cancer Hospital) Guan, Yan (Department of Medical Oncology, Shandong Cancer Hospital) Zhang, Chu-Feng (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences) Wang, Peng (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences) Li, Yan (Department of Medical Oncology, Shandong Cancer Hospital) Guo, Qi-Sen (Department of Medical Oncology, Shandong Cancer Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제14호

발행연도: 2014.1

수록면: 5,697 - 5,699 (3page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: To investigate the optimal timing of radiotherapy with alternating/sequential radio-chemotherapy for limited-stage small cell lung cancer (LS-SCLC). Methods: 91 patients with LS-SCLC were retrospectively analyzed and divided into two groups according to the number of chemotherapy cycles before radiotherapy. If the patient received radiotherapy after 3 cycles or fewer cycles of chemotherapy, classification was into the early group, if not, into the late group. All patients received 6 cycles of standard chemotherapy (EP/EC) and conventional radiotherapy (56 gy~ 60 gy/28 f ~30 f). Results: The response rate (RR) of the early and late groups were 85.7% and 81.6%, respectively, with no significant difference (p>0.05). In contrast, the progression-free survival (PFS) in the early group was better than that in the late group (11.8 months vs 9.86 months), and the difference was significant (p<0.05). There was no significant difference between two groups in adverse reactions, which gastrointestinal irritation and bone marrow suppression being the most common (p>0.05). Conclusions: Radiotherapy after 3 cycles or fewer cycles of chemotherapy does not bring significant benefits for RR of patients with LS-SCLC, but it could significantly prolong their PFS without increase in adverse reactions.

#Carcinoma #small cell lung cancer #chemotherapy #radiotherapy #timing

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Wang, Li-Jie

소속기관 School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences